Budesonide and Flutimavir can both be used in the treatment of chronic obstructive pulmonary disease (COPD), each with its own characteristics, there is no difference between good and bad, suitable for the patient’s condition is better. Budegraf belongs to the compound preparation, containing budesonide, glononium and formoterol fumarate, mainly used for the maintenance treatment of patients with chronic obstructive pulmonary disease. Common adverse effects of this product include oral candidiasis, palpitations, cough and nausea, and it is contraindicated in patients who are allergic to any of the components in this product. Flutimavir is composed of fluticasone furoate, umeclidinium bromide and vilanterol triphenylacetate, and this product is also used clinically for the treatment of chronic obstructive pulmonary disease. The most common adverse reactions to this product are headache, nasopharyngitis and upper respiratory tract infections, and it is contraindicated in people who are allergic to this product. Budegraf and Flutimavir both belong to the long-term treatment of chronic obstructive pulmonary disease, but there are differences in their methods of use and adverse reactions, it is recommended that patients use them under the guidance of a doctor, do not use them without authorization, to avoid causing adverse reactions.